Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS Peptide Vaccine + Chemoimmunotherapy in Advanced KRAS Mutated NSCLC
NCT05254184Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mKRASvax in non-small cell lung cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety assessed by adverse events at 29 days and Feasibility assessed by adverse events at 29 days. Started Nov 2022; status: recruiting.
02
Drugs
mKRASvax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05254184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254184.